Efficacy and Safety of Ambrisentan in Children 8-18yrs
A Randomized, Open Label Study Comparing Safety and Efficacy Parameters for a High and a Low Dose of Ambrisentan (Adjusted for Body Weight) for the Treatment of Pulmonary Arterial Hypertension in Paediatric Patients Aged 8 Years up to 18 Years
Sponsor: GlaxoSmithKline
Terminated
Ongoing juvenile rat toxicology studies.
Other terminated trials from GlaxoSmithKline
Other Hypertension, Pulmonary trials with similar outcome
A PHASE2 clinical study on Hypertension, Pulmonary, this trial is terminated or withdrawn. The trial is conducted by GlaxoSmithKline and has accumulated 13 data snapshots since 2011. Cardiovascular trials of this type often inform treatment guidelines for long-term patient management.
Status Flow
Change History
13 versions recorded-
Sep 2025 — Present [monthly]
Terminated PHASE2
-
Sep 2024 — Sep 2025 [monthly]
Terminated PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE2
-
Jan 2021 — Jul 2024 [monthly]
Terminated PHASE2
-
Nov 2019 — Jan 2021 [monthly]
Terminated PHASE2
▶ Show 8 earlier versions
-
Aug 2019 — Nov 2019 [monthly]
Terminated PHASE2
Status: Suspended → Terminated
-
Nov 2018 — Aug 2019 [monthly]
Suspended PHASE2
-
Jul 2018 — Nov 2018 [monthly]
Suspended PHASE2
-
Jun 2018 — Jul 2018 [monthly]
Suspended PHASE2
-
Mar 2018 — Jun 2018 [monthly]
Suspended PHASE2
-
Apr 2017 — Mar 2018 [monthly]
Suspended PHASE2
-
Feb 2017 — Apr 2017 [monthly]
Suspended PHASE2
-
Jan 2017 — Feb 2017 [monthly]
Suspended PHASE2
First recorded
Jan 2011
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- GlaxoSmithKline
For direct contact, visit the study record on ClinicalTrials.gov .